Development of synthetic immunotoxin that can enable ABC incompatible transplantation and xenotransplantation.
| Project/Area Number |
16390364
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | HIR0SHIMA UNIVERSITY |
|---|
Principal Investigator |
ASAHARA Toshimasa Hiroshima university, Hospital, Professor, 病院, 教授 (70175850)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHDAN Hideki Hiroshima university, Hospital, Research Associate, 病院・助手 (10363061)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥14,100,000 (Direct Cost: ¥14,100,000)
Fiscal Year 2005: ¥6,800,000 (Direct Cost: ¥6,800,000)
Fiscal Year 2004: ¥7,300,000 (Direct Cost: ¥7,300,000)
|
|---|
| Keywords | Xenotransplantation / ABO-incompatible transplantation / Rejection / B cells / Immunotoxin |
|---|
| Research Abstract |
The establishment of a novel method for persistent elimination of B cells responding to transplantation associated carbohydrates : We have demonstrated that B cells bearing receptors that recognize blood group A carbohydrates are found exclusively in the sIgM^+ CD11b^+ CD5^+ B-1 subset in the peripheral blood of humans with blood group O or B. Some reports suggest that the segregation to B-1 cells probably occurs via Ig gene rearrangement on stimulation with thymus-independent type 2 antigens. We have proved that cyclosporin A (CsA) and Tacrolimus (Tac) blocks such segregation to B-1 cells, although CsA has no effect on Ab-producing cells or differentiated B-1 cells. Based on these facts, we hypothesize that the specific elimination of both Ab-producing cells and differentiated B-1 cells with anti-A/B specificity and subsequent CsA/Tac therapy might lead to the long lasting inhibition of anti-A/B Ab production in ABO-incompatible organ transplantation. Balb/c mice resemble humans with
… More
blood group O or B in that the mice have natural Abs against human blood group A carbohydrates in their sera. B cells bearing receptors that recognize these A carbohydrates in mice also belong to the CD5^+ CD11b^+ B-1 subset. The ability of synthetic A carbohydrates (GalNAcα1-3Fucα1-2Gal) conjugated with BSA and rabbit anti-BSA Abs to deplete anti-A IgM-producing cells was studied in vitro. The Balb/c mice were first injected with A-BSA and then with anti-BSA Abs after 6 hours. In mice that received the injection of A-BSA/anti-BSA Abs, the serum levels of anti-A IgM reduced by day 14. However, immunization with human A RBCs on day 14 resulted in an increase in the serum levels of anti-A Abs. In contrast, when combined with the CsA treatment and treatment with A-BSA/anti-BSA Abs, the serum levels of anti-A Abs were persistently undetectable in the mice even after the immunization. These results are consistent with the hypotheses that treatment with A-BSA/anti-BSA Abs temporally depletes B cells responding to A determinants, and that CsA/Tac treatment prevents the replenishment of these cells. The establishment of a model for analyses of B cells responding to N-glycolylneuraminic acid : The presence in humans of natural antibodies directed against N-glycolylneuraminic acid (NeuGc) epitopes on pig vascular endothelium may provides another barrier in xenotransplantation, as antibody-antigen binding leads to rejection. There has been no animal model for analyses of B cells responding to NeuGcso far. We have established a in vivo model utilizing NeuGc-deficient mice. Less
|
Report
(3 results)
Research Products
(18 results)
